Novo Nordisk Increases Revenue and Profit! Wegovy is Heavily Impacted by Copycat Products! Forecast for 2025 Lowered!

The global healthcare company Novo Nordisk (NVO) published its business report for the first quarter of 2025 on May 7, 2025, before the market opened and was able to expand its revenues, even though sales of the obesity drug Wegovy fell short of expectations. Net profit exceeded analysts' expectations. Nevertheless, Novo Nordisk had to lower its forecasts for the year 2025. The stock rose significantly by over 5% in pre-market trading to nearly $70. Obesity medications achieve revenue growth of 67% The Danish pharmaceutical manufacturer was...